APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Infective Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Infective Vaccines Market Outlook and Growth Opportunities 2026

21 December 2025202 pages

Choose your research edition.

Industry ResearchAnti-Infective Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Infective Vaccines Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Anti-Infective Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Infective Vaccines Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Infective Vaccines Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Anti-Infective Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Infective Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Infective Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Infective Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Infective Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Infective Vaccines market include Sanofi Pasteur, Novartis Vaccines, Merck & Co., GlaxoSmithKline Biologicals, Wyeth Pharmaceuticals, Inc., Protein Sciences Co., Organon Teknika Co., MedImmune LLC and MassBiologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Infective Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Infective Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Infective Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Infective Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Infective Vaccines Segment by Company

Sanofi Pasteur

Novartis Vaccines

Merck & Co.

GlaxoSmithKline Biologicals

Wyeth Pharmaceuticals, Inc.

Protein Sciences Co.

Organon Teknika Co.

MedImmune LLC

MassBiologics

Intercell Biomedical

ID Biomedical Co.

Emergent BioDefense Operations Lansing Inc.

Diagnostics Ltd.

CSL Ltd.

Berna Biotech

Barr Labs, Inc.

Anti-Infective Vaccines Segment by Type

Inactivated Vaccines

Live/attenuated Vaccines

Conjugate Vaccines

Anti-Infective Vaccines Segment by Application

Bacterial Diseases

Viral Diseases

Anti-Infective Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Infective Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Infective Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Infective Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Infective Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Infective Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Infective Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Infective Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Infective Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Infective Vaccines industry.

Chapter 3: Detailed analysis of Anti-Infective Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Infective Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Infective Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Infective Vaccines Industry Trends Table 2. Anti-Infective Vaccines Industry Drivers Table 3. Anti-Infective Vaccines Industry Opportunities and Challenges Table 4. Anti-Infective Vaccines Industry Restraints Table 5. Global Anti-Infective Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Infective Vaccines Revenue Share by Company (2021-2026) Table 7. Global Anti-Infective Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Anti-Infective Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Infective Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Anti-Infective Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Infective Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Infective Vaccines Company, Product Type & Application Table 13. Global Anti-Infective Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Infective Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Inactivated Vaccines Table 18. Significant Companies of Live/attenuated Vaccines Table 19. Significant Companies of Conjugate Vaccines Table 20. Global Anti-Infective Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Anti-Infective Vaccines Sales Volume by Type (2021-2026) & (k units) Table 22. Global Anti-Infective Vaccines Sales Volume by Type (2027-2032) & (k units) Table 23. Global Anti-Infective Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global Anti-Infective Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global Anti-Infective Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Anti-Infective Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Anti-Infective Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Anti-Infective Vaccines Sales Value Share by Type (2021-2026) Table 29. Global Anti-Infective Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Bacterial Diseases Table 31. Significant Companies of Viral Diseases Table 32. Global Anti-Infective Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Anti-Infective Vaccines Sales Volume by Application (2021-2026) & (k units) Table 34. Global Anti-Infective Vaccines Sales Volume by Application (2027-2032) & (k units) Table 35. Global Anti-Infective Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global Anti-Infective Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global Anti-Infective Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-Infective Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Anti-Infective Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Anti-Infective Vaccines Sales Value Share by Application (2021-2026) Table 41. Global Anti-Infective Vaccines Sales Value Share by Application (2027-2032) Table 42. Global Anti-Infective Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Anti-Infective Vaccines Sales by Region (2021-2026) & (k units) Table 44. Global Anti-Infective Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Anti-Infective Vaccines Sales by Region (2027-2032) & (k units) Table 46. Global Anti-Infective Vaccines Sales Market Share by Region (2027-2032) Table 47. Global Anti-Infective Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-Infective Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Anti-Infective Vaccines Sales Value Share by Region (2021-2026) Table 50. Global Anti-Infective Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Anti-Infective Vaccines Sales Value Share by Region (2027-2032) Table 52. Global Anti-Infective Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Anti-Infective Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Anti-Infective Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Anti-Infective Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Anti-Infective Vaccines Sales by Country (2021-2026) & (k units) Table 57. Global Anti-Infective Vaccines Sales Market Share by Country (2021-2026) Table 58. Global Anti-Infective Vaccines Sales by Country (2027-2032) & (k units) Table 59. Global Anti-Infective Vaccines Sales Market Share by Country (2027-2032) Table 60. Global Anti-Infective Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Anti-Infective Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global Anti-Infective Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Anti-Infective Vaccines Sales Value Market Share by Country (2027-2032) Table 64. Sanofi Pasteur Company Information Table 65. Sanofi Pasteur Business Overview Table 66. Sanofi Pasteur Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Sanofi Pasteur Anti-Infective Vaccines Product Portfolio Table 68. Sanofi Pasteur Recent Development Table 69. Novartis Vaccines Company Information Table 70. Novartis Vaccines Business Overview Table 71. Novartis Vaccines Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Novartis Vaccines Anti-Infective Vaccines Product Portfolio Table 73. Novartis Vaccines Recent Development Table 74. Merck & Co. Company Information Table 75. Merck & Co. Business Overview Table 76. Merck & Co. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Merck & Co. Anti-Infective Vaccines Product Portfolio Table 78. Merck & Co. Recent Development Table 79. GlaxoSmithKline Biologicals Company Information Table 80. GlaxoSmithKline Biologicals Business Overview Table 81. GlaxoSmithKline Biologicals Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Biologicals Anti-Infective Vaccines Product Portfolio Table 83. GlaxoSmithKline Biologicals Recent Development Table 84. Wyeth Pharmaceuticals, Inc. Company Information Table 85. Wyeth Pharmaceuticals, Inc. Business Overview Table 86. Wyeth Pharmaceuticals, Inc. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Wyeth Pharmaceuticals, Inc. Anti-Infective Vaccines Product Portfolio Table 88. Wyeth Pharmaceuticals, Inc. Recent Development Table 89. Protein Sciences Co. Company Information Table 90. Protein Sciences Co. Business Overview Table 91. Protein Sciences Co. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Protein Sciences Co. Anti-Infective Vaccines Product Portfolio Table 93. Protein Sciences Co. Recent Development Table 94. Organon Teknika Co. Company Information Table 95. Organon Teknika Co. Business Overview Table 96. Organon Teknika Co. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Organon Teknika Co. Anti-Infective Vaccines Product Portfolio Table 98. Organon Teknika Co. Recent Development Table 99. MedImmune LLC Company Information Table 100. MedImmune LLC Business Overview Table 101. MedImmune LLC Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. MedImmune LLC Anti-Infective Vaccines Product Portfolio Table 103. MedImmune LLC Recent Development Table 104. MassBiologics Company Information Table 105. MassBiologics Business Overview Table 106. MassBiologics Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. MassBiologics Anti-Infective Vaccines Product Portfolio Table 108. MassBiologics Recent Development Table 109. Intercell Biomedical Company Information Table 110. Intercell Biomedical Business Overview Table 111. Intercell Biomedical Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Intercell Biomedical Anti-Infective Vaccines Product Portfolio Table 113. Intercell Biomedical Recent Development Table 114. ID Biomedical Co. Company Information Table 115. ID Biomedical Co. Business Overview Table 116. ID Biomedical Co. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. ID Biomedical Co. Anti-Infective Vaccines Product Portfolio Table 118. ID Biomedical Co. Recent Development Table 119. Emergent BioDefense Operations Lansing Inc. Company Information Table 120. Emergent BioDefense Operations Lansing Inc. Business Overview Table 121. Emergent BioDefense Operations Lansing Inc. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Emergent BioDefense Operations Lansing Inc. Anti-Infective Vaccines Product Portfolio Table 123. Emergent BioDefense Operations Lansing Inc. Recent Development Table 124. Diagnostics Ltd. Company Information Table 125. Diagnostics Ltd. Business Overview Table 126. Diagnostics Ltd. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Diagnostics Ltd. Anti-Infective Vaccines Product Portfolio Table 128. Diagnostics Ltd. Recent Development Table 129. CSL Ltd. Company Information Table 130. CSL Ltd. Business Overview Table 131. CSL Ltd. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. CSL Ltd. Anti-Infective Vaccines Product Portfolio Table 133. CSL Ltd. Recent Development Table 134. Berna Biotech Company Information Table 135. Berna Biotech Business Overview Table 136. Berna Biotech Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Berna Biotech Anti-Infective Vaccines Product Portfolio Table 138. Berna Biotech Recent Development Table 139. Barr Labs, Inc. Company Information Table 140. Barr Labs, Inc. Business Overview Table 141. Barr Labs, Inc. Anti-Infective Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Barr Labs, Inc. Anti-Infective Vaccines Product Portfolio Table 143. Barr Labs, Inc. Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Anti-Infective Vaccines Distributors List Table 147. Anti-Infective Vaccines Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Anti-Infective Vaccines Product Image Figure 2. Global Anti-Infective Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Infective Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Infective Vaccines Sales (2021-2032) & (k units) Figure 5. Global Anti-Infective Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Anti-Infective Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Inactivated Vaccines Image Figure 10. Live/attenuated Vaccines Image Figure 11. Conjugate Vaccines Image Figure 12. Global Anti-Infective Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Anti-Infective Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Anti-Infective Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global Anti-Infective Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Anti-Infective Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Anti-Infective Vaccines Sales Value Share by Type (2021-2032) Figure 18. Bacterial Diseases Image Figure 19. Viral Diseases Image Figure 20. Global Anti-Infective Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Anti-Infective Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-Infective Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global Anti-Infective Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-Infective Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-Infective Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global Anti-Infective Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Anti-Infective Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Anti-Infective Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Anti-Infective Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Anti-Infective Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America Anti-Infective Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Anti-Infective Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Anti-Infective Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Anti-Infective Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Anti-Infective Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Anti-Infective Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America Anti-Infective Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Anti-Infective Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Anti-Infective Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Anti-Infective Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Anti-Infective Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Anti-Infective Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccines
  • Live/attenuated Vaccines
  • Conjugate Vaccines
Applications
  • Bacterial Diseases
  • Viral Diseases
Companies covered
  • Sanofi Pasteur
  • Novartis Vaccines
  • Merck & Co.
  • GlaxoSmithKline Biologicals
  • Wyeth Pharmaceuticals, Inc.
  • Protein Sciences Co.
  • Organon Teknika Co.
  • MedImmune LLC
  • MassBiologics
  • Intercell Biomedical
  • ID Biomedical Co.
  • Emergent BioDefense Operations Lansing Inc.
  • Diagnostics Ltd.
  • CSL Ltd.
  • Berna Biotech
  • Barr Labs, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Infective Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Infective Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Infective Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Infective Vaccines Market Dynamics
  1. 2.1 Anti-Infective Vaccines Industry Trends
  2. 2.2 Anti-Infective Vaccines Industry Drivers
  3. 2.3 Anti-Infective Vaccines Industry Opportunities and Challenges
  4. 2.4 Anti-Infective Vaccines Industry Restraints
3 Anti-Infective Vaccines Market by Company
  1. 3.1 Global Anti-Infective Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Infective Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Infective Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Infective Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Infective Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Anti-Infective Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Infective Vaccines Company Product Type and Application
  8. 3.8 Global Anti-Infective Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Infective Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Infective Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Infective Vaccines Market by Type
  1. 4.1 Anti-Infective Vaccines Type Introduction
  2. 4.1.1 Inactivated Vaccines
  3. 4.1.2 Live/attenuated Vaccines
  4. 4.1.3 Conjugate Vaccines
  5. 4.2 Global Anti-Infective Vaccines Sales Volume by Type
  6. 4.2.1 Global Anti-Infective Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Anti-Infective Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Anti-Infective Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Anti-Infective Vaccines Sales Value by Type
  10. 4.3.1 Global Anti-Infective Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Anti-Infective Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global Anti-Infective Vaccines Sales Value Share by Type (2021-2032)
5 Anti-Infective Vaccines Market by Application
  1. 5.1 Anti-Infective Vaccines Application Introduction
  2. 5.1.1 Bacterial Diseases
  3. 5.1.2 Viral Diseases
  4. 5.2 Global Anti-Infective Vaccines Sales Volume by Application
  5. 5.2.1 Global Anti-Infective Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anti-Infective Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Anti-Infective Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Anti-Infective Vaccines Sales Value by Application
  9. 5.3.1 Global Anti-Infective Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Anti-Infective Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Anti-Infective Vaccines Sales Value Share by Application (2021-2032)
6 Anti-Infective Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Anti-Infective Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Infective Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Infective Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Infective Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Anti-Infective Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Infective Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Infective Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Infective Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Infective Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Infective Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Infective Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Infective Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Infective Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Infective Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Infective Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Infective Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Infective Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Infective Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Infective Vaccines Sales Value Share by Country, 2025 VS 2032
7 Anti-Infective Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Infective Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Infective Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Infective Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Infective Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Infective Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Anti-Infective Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Infective Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Infective Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Infective Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Infective Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Infective Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur
  2. 8.1.1 Sanofi Pasteur Company Information
  3. 8.1.2 Sanofi Pasteur Business Overview
  4. 8.1.3 Sanofi Pasteur Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur Anti-Infective Vaccines Product Portfolio
  6. 8.1.5 Sanofi Pasteur Recent Developments
  7. 8.2 Novartis Vaccines
  8. 8.2.1 Novartis Vaccines Company Information
  9. 8.2.2 Novartis Vaccines Business Overview
  10. 8.2.3 Novartis Vaccines Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Vaccines Anti-Infective Vaccines Product Portfolio
  12. 8.2.5 Novartis Vaccines Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Anti-Infective Vaccines Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 GlaxoSmithKline Biologicals
  20. 8.4.1 GlaxoSmithKline Biologicals Company Information
  21. 8.4.2 GlaxoSmithKline Biologicals Business Overview
  22. 8.4.3 GlaxoSmithKline Biologicals Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Biologicals Anti-Infective Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline Biologicals Recent Developments
  25. 8.5 Wyeth Pharmaceuticals, Inc.
  26. 8.5.1 Wyeth Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Wyeth Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Wyeth Pharmaceuticals, Inc. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Wyeth Pharmaceuticals, Inc. Anti-Infective Vaccines Product Portfolio
  30. 8.5.5 Wyeth Pharmaceuticals, Inc. Recent Developments
  31. 8.6 Protein Sciences Co.
  32. 8.6.1 Protein Sciences Co. Company Information
  33. 8.6.2 Protein Sciences Co. Business Overview
  34. 8.6.3 Protein Sciences Co. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Protein Sciences Co. Anti-Infective Vaccines Product Portfolio
  36. 8.6.5 Protein Sciences Co. Recent Developments
  37. 8.7 Organon Teknika Co.
  38. 8.7.1 Organon Teknika Co. Company Information
  39. 8.7.2 Organon Teknika Co. Business Overview
  40. 8.7.3 Organon Teknika Co. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Organon Teknika Co. Anti-Infective Vaccines Product Portfolio
  42. 8.7.5 Organon Teknika Co. Recent Developments
  43. 8.8 MedImmune LLC
  44. 8.8.1 MedImmune LLC Company Information
  45. 8.8.2 MedImmune LLC Business Overview
  46. 8.8.3 MedImmune LLC Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 MedImmune LLC Anti-Infective Vaccines Product Portfolio
  48. 8.8.5 MedImmune LLC Recent Developments
  49. 8.9 MassBiologics
  50. 8.9.1 MassBiologics Company Information
  51. 8.9.2 MassBiologics Business Overview
  52. 8.9.3 MassBiologics Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 MassBiologics Anti-Infective Vaccines Product Portfolio
  54. 8.9.5 MassBiologics Recent Developments
  55. 8.10 Intercell Biomedical
  56. 8.10.1 Intercell Biomedical Company Information
  57. 8.10.2 Intercell Biomedical Business Overview
  58. 8.10.3 Intercell Biomedical Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Intercell Biomedical Anti-Infective Vaccines Product Portfolio
  60. 8.10.5 Intercell Biomedical Recent Developments
  61. 8.11 ID Biomedical Co.
  62. 8.11.1 ID Biomedical Co. Company Information
  63. 8.11.2 ID Biomedical Co. Business Overview
  64. 8.11.3 ID Biomedical Co. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 ID Biomedical Co. Anti-Infective Vaccines Product Portfolio
  66. 8.11.5 ID Biomedical Co. Recent Developments
  67. 8.12 Emergent BioDefense Operations Lansing Inc.
  68. 8.12.1 Emergent BioDefense Operations Lansing Inc. Company Information
  69. 8.12.2 Emergent BioDefense Operations Lansing Inc. Business Overview
  70. 8.12.3 Emergent BioDefense Operations Lansing Inc. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Emergent BioDefense Operations Lansing Inc. Anti-Infective Vaccines Product Portfolio
  72. 8.12.5 Emergent BioDefense Operations Lansing Inc. Recent Developments
  73. 8.13 Diagnostics Ltd.
  74. 8.13.1 Diagnostics Ltd. Company Information
  75. 8.13.2 Diagnostics Ltd. Business Overview
  76. 8.13.3 Diagnostics Ltd. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Diagnostics Ltd. Anti-Infective Vaccines Product Portfolio
  78. 8.13.5 Diagnostics Ltd. Recent Developments
  79. 8.14 CSL Ltd.
  80. 8.14.1 CSL Ltd. Company Information
  81. 8.14.2 CSL Ltd. Business Overview
  82. 8.14.3 CSL Ltd. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 CSL Ltd. Anti-Infective Vaccines Product Portfolio
  84. 8.14.5 CSL Ltd. Recent Developments
  85. 8.15 Berna Biotech
  86. 8.15.1 Berna Biotech Company Information
  87. 8.15.2 Berna Biotech Business Overview
  88. 8.15.3 Berna Biotech Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Berna Biotech Anti-Infective Vaccines Product Portfolio
  90. 8.15.5 Berna Biotech Recent Developments
  91. 8.16 Barr Labs, Inc.
  92. 8.16.1 Barr Labs, Inc. Company Information
  93. 8.16.2 Barr Labs, Inc. Business Overview
  94. 8.16.3 Barr Labs, Inc. Anti-Infective Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Barr Labs, Inc. Anti-Infective Vaccines Product Portfolio
  96. 8.16.5 Barr Labs, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Infective Vaccines Value Chain Analysis
  2. 9.1.1 Anti-Infective Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Infective Vaccines Sales Mode & Process
  6. 9.2 Anti-Infective Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Infective Vaccines Distributors
  9. 9.2.3 Anti-Infective Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst